AlgoTx

Suresnes, France Founded: 2018 • Age: 8 yrs
Therapeutic solutions for pain management are developed by AlgoTx.

About AlgoTx

AlgoTx is a company based in Suresnes (France) founded in 2018 by Stephane Thiroloix and Olivier Bohuon. It operates as a HealthTech. AlgoTx has raised $39.29 million across 4 funding rounds from investors including Bpifrance, Relyens and Omnes Capital. AlgoTx offers products and services including ATX01. AlgoTx operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.

  • Headquarter Suresnes, France
  • Founders Stephane Thiroloix, Olivier Bohuon
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $39.29 M (USD)

    in 4 rounds

  • Latest Funding Round
    $21.42 M (USD), Series B

    Mar 14, 2023

  • Investors
    Bpifrance

    & 3 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of AlgoTx

AlgoTx offers a comprehensive portfolio of products and services, including ATX01. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

ATX01 is developed for complex pain relief treatment.

People of AlgoTx
Headcount 1-10
Employee Profiles 3
Employee Profiles
People
Etienne Bienfait
CFO
People
Stéphane Thiroloix
President & CEO
People
Philippe Picaut
Chief Development Officer

Unlock access to complete

Funding Insights of AlgoTx

AlgoTx has successfully raised a total of $39.29M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $21.42 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series B — $21.4M
  • First Round

    (01 Jun 2018)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2023 Amount Series B - AlgoTx Valuation Relyens
Nov, 2020 Amount Series A - AlgoTx Valuation Bpifrance
Nov, 2019 Amount Seed - AlgoTx Valuation Bpifrance
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in AlgoTx

AlgoTx has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, Relyens and Omnes Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity firm focused on energy transition and sustainable investments across Europe.
Founded Year Domain Location
UI Investissement is engaged in private equity and investment services.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by AlgoTx

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - AlgoTx

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Algotx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of AlgoTx

AlgoTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of therapies for the treatment of musculoskeletal disorders
domain founded_year HQ Location
Developer of therapeutics for pain relief and inflammatory diseases
domain founded_year HQ Location
Develops antibody-based treatments for autoimmune and inflammatory disorders.
domain founded_year HQ Location
Therapies for pain and addiction treatment are developed.
domain founded_year HQ Location
Drug delivery systems for CNS disorders and pain are developed.
domain founded_year HQ Location
Pain treatment products are developed through reformulation technologies.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Algotx

Frequently Asked Questions about AlgoTx

When was AlgoTx founded?

AlgoTx was founded in 2018.

Where is AlgoTx located?

AlgoTx is headquartered in Suresnes, France. It is registered at Suresnes, Ile-de-france, France.

Who is the current CEO of AlgoTx?

Stephane Thiroloix is the current CEO of AlgoTx. They have also founded this company.

Is AlgoTx a funded company?

AlgoTx is a funded company, having raised a total of $39.29M across 4 funding rounds to date. The company's 1st funding round was a Seed of $553.74K, raised on Jun 01, 2018.

What does AlgoTx do?

AlgoTx is engaged in the development of novel non-opioid solutions for complex pain relief. The company prioritizes indications lacking proven therapies, such as Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Erythromelalgia. Its lead program, ATX01, is in Phase 2 clinical development, targeting specific patient needs through topical administration to minimize systemic side effects. Operations are based in France, with research and clinical trials conducted in the US and Europe.

Who are the top competitors of AlgoTx?

AlgoTx's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.

What products or services does AlgoTx offer?

AlgoTx offers ATX01.

Who are AlgoTx's investors?

AlgoTx has 4 investors. Key investors include Bpifrance, Relyens, Omnes Capital, and UI Investissement.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available